APUS DEF 14A: Board change
Apimeds Pharmaceuticals US
Filed with the SEC on · accession 0001213900-26-121888
APUS filed a DEF 14A (proxy statement) with the SEC on Nov 18, 2026. Information for the shareholder meeting: votes, board members and executive pay.
Summary of the filing
Apimeds Pharmaceuticals US filed a definitive proxy statement for its 2026 annual meeting, asking stockholders to elect four directors, ratify the appointment of Kreit & Chiu CPA LLP as independent auditor, and approve an adjournment proposal if needed.
Key details
✦ Ask GOAX AI about this filing — what it means for APUS, what changed since its last filings and what to watch next.
Try it free for 7 days🔔 Want to stay updated on new SEC filings for APUS?
Click hereFrequently asked questions
What did APUS file with the SEC on Nov 18, 2026?
APUS filed a DEF 14A (Board change). Apimeds Pharmaceuticals US filed a definitive proxy statement for its 2026 annual meeting, asking stockholders to elect four directors, ratify the appointment of Kreit & Chiu CPA LLP as independent auditor, and approve an adjournment proposal if needed.
What does a board change mean for APUS stock?
Not always. A planned retirement with a successor is usually calm; a sudden departure “effective immediately”, especially of a CFO or near results, often worries investors.
How do I read a DEF 14A?
Information for the shareholder meeting: votes, board members and executive pay. Executive pay tables show how management is paid. Check the items shareholders vote on (mergers, new share plans).
Why are SEC filings important?
Public companies must tell the SEC about anything that can change their value — results, leadership changes, big deals, new shares, bankruptcy. Filings are the official source, often before the news. A DEF 14A (proxy statement): Information for the shareholder meeting: votes, board members and executive pay.
Other APUS SEC filings
Get alerts when APUS files with the SEC, plus live charts, key levels and news for 13,000+ stocks.
Try SEPT free for 7 days